GLP-1 'grind' culture on TikTok: what the science says

What did @loseitwithliz__ actually say?

Honestly? It's hard to tell. The transcript captured here is largely incoherent, likely the result of a failed auto-transcription of background music, overlapping audio, or a trending audio clip playing over the video. What's actually audible doesn't constitute a clear health claim about GLP-1 medications or weight loss.

The caption reads "Keep on grinding" with a sparkle emoji, which is motivational language common in weight loss content. Without a clean transcript, we can't fairly attribute specific medical claims to this creator. What we can do is address what GLP-1 content creators in this niche typically say, and whether those common claims hold up to scrutiny.

Assigning an accuracy rating to garbled audio would be irresponsible. If you watched this video and heard something specific about semaglutide, tirzepatide, or weight loss, the claims below address the most common talking points in this space.

Does the science back up common GLP-1 claims on TikTok?

For the actual medications, yes, there is real and substantial evidence. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide produced up to 22.5% mean body weight reduction over 72 weeks. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide 2.4mg produced roughly 15% weight loss versus 2.4% for placebo.

That said, TikTok GLP-1 content frequently overstates how effortless these results are, understates side effect profiles, and conflates compounded versions with brand-name drugs. The drugs work, but the social media narrative around them often glosses over that most participants in trials still experienced nausea, vomiting, or gastrointestinal distress, and that weight regain after stopping is well-documented (Wilding et al., 2022, Diabetes, Obesity and Metabolism).

What did they get wrong, or right?

We can't call this creator out specifically for a claim they may not have made. The audio is not usable. What we can say is that the "keep grinding" framing around GLP-1 use is a double-edged message. On one hand, it normalizes persistence in a weight loss journey, which has psychological value. On the other hand, it can imply that outcomes depend primarily on effort, when GLP-1 medications are pharmacological interventions, not motivation tools.

• GLP-1 receptor agonists reduce appetite partly by slowing gastric emptying and acting on hypothalamic satiety centers, not by rewarding harder effort.
• Framing medication-assisted weight loss as "grinding" may inadvertently stigmatize people who struggle without medication, or create unrealistic expectations about what the drugs do.
• Without a clear claim, there is nothing here to fact-check as accurate or inaccurate.

What should you actually know?

If you're watching GLP-1 content on TikTok, here's what the research actually supports. Semaglutide and tirzepatide are among the most effective pharmacological weight loss tools studied to date. Neither is a cure for obesity, and neither works the same for everyone. Response varies significantly based on genetics, diet, baseline metabolic health, and adherence.

Compounded semaglutide or tirzepatide, which many creators and clinics promote, is not the same as FDA-approved Wegovy, Ozempic, Mounjaro, or Zepbound. The FDA has explicitly warned that compounded versions are not bioequivalent and have not undergone the same approval process. This matters when you're making a decision about your health, not just your feed.

Any telehealth platform or creator telling you these medications require no lifestyle context, have no meaningful side effects, or will work identically regardless of formulation is skipping over evidence you deserve to have.